SEARCH:   Advanced

Blood, 1 September 2004, Vol. 104, No. 5, pp. 1534-1541. Prepublished online as a Blood First Edition Paper on May 11, 2004; DOI 10.1182/blood-2003-12-4443. This Article Full Text (PDF) All Versions of this Article: 2003-12-4443v1 104/5/1534    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by McCullough, J. Articles by Conlan, M. Search for Related Content PubMed PubMed Citation Articles by McCullough, J. Articles by Conlan, M. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted January 8, 2004 Accepted April 12, 2004 Therapeutic Efficacy and Safety of Platelets Treated with a Photochemical Process for Pathogen Inactivation: The SPRINT Trial Jeffrey McCullough*, David H Vesole, Richard J Benjamin, Sherrill J Slichter, Alvaro Pineda, Edward Snyder, Edward Stadtmauer, Ileana Lopez-Plaza, Steven Coutre, Ronald G Strauss, Lawrence T Goodnough, Joy L Fridey, Thomas Raife, Ritchard Cable, Scott Murphy, Frank Howard, Kathryn Davis, Jin-Sying Lin, Peyton Metzel, Laurence Corash, Antonis Koutsoukos, Lily Lin, Donald Buchholz, and Maureen Conlan Lab. Med. & Path., University of Minnesota, Minneapolis, MN, USA Blood & Marrow Transplant Program, Medical College of Wisconsin, Milwaukee, WI, USA Transfusion Medicine, Brigham & Women's Hospital, Boston, MA, USA Transfusion Medicine, Puget Sound Blood Center, Seattle, WA, USA Transfusion Medicine, Mayo Clinic, Rochester, MN, USA School of Medicine, Yale-New Haven Hospital, New Haven, CT, USA University of Pennsylvania Medical Center, Philadelphia, PA, USA Institute for Transfusion Medicine, Pittsburgh, PA, USA Stanford Medical Center, Palo Alto, CA, USA DeGowin Blood Center, University of Iowa, Iowa City, IA, USA Washington University School of Medicine, St. Louis, MO, USA Blood Bank of San Bernadino County, San Bernadino, CA, USA Blood Center of Southeastern Wisconsin, Milwaukee, WI, USA American Red Cross Blood Services, Farmington, CT, USA Penn-Jersey Region, American Red Cross Blood Services, Philadelphia, PA, USA Loma Linda University Cancer Institute, Loma Linda, CA, USA University of Washington, Seattle, WA, USA Cerus Corporation, Concord, CA, USA Baxter Healthcare Corporation, Round Lake, IL, USA Quintiles, Inc., Rockville, MD, USA * Corresponding author; email: mccul001{at}umn.edu. We report a transfusion trial of platelets photochemically treated for pathogen inactivation using the synthetic psoralen amotosalen HCl. Thrombocytopenic patients were randomized to receive either photochemically treated (PCT) or conventional (control) platelets for up to 28 days. The primary endpoint was the proportion of patients with WHO Grade 2 bleeding during the period of platelet support. 645 patients (318 PCT vs. 327 control) were evaluated. The primary endpoint, the incidence of Grade 2 bleeding (58.5% PCT vs. 57.5% control), and the secondary endpoint, the incidence of Grade 3 or 4 bleeding (4.1% PCT vs. 6.1% control), were equivalent between the two groups (p < .001 by non-inferiority). The mean 1-hour post transfusion platelet corrected count increment (CCI) (11.1 x 103 PCT vs. 16.0 x 103 control), average number of days-to-next platelet transfusion (1.9 PCT vs. 2.4 control), and number of platelet transfusions (8.4 PCT vs. 6.2 control) were different (p < 0.001). Transfusion reactions were fewer following PCT platelets (3.0% PCT vs. 4.4% control; p = 0.02). The incidence of Grade 2 bleeding was equivalent for PCT and conventional platelets, although post-transfusion platelet count increments and days-to-next transfusion were decreased for PCT compared to conventional platelets. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. E. Hendrickson and C. D. Hillyer Noninfectious Serious Hazards of Transfusion Anesth. Analg., March 1, 2009; 108(3): 759 - 769. [Abstract] [Full Text] [PDF] N. M. Heddle, R. J. Cook, A. Tinmouth, C. T. Kouroukis, T. Hervig, E. Klapper, J. M. Brandwein, Z. M. Szczepiorkowski, J. P. AuBuchon, R. L. Barty, et al. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia Blood, February 12, 2009; 113(7): 1564 - 1573. [Abstract] [Full Text] [PDF] T. R. Klumpp and D. L. Siegel Transfusion medicine ASH Self-Assessment Program, January 1, 2007; 2007(1): 408 - 443. [Full Text] [PDF] P. D. Mintz, N. M. Bass, L. D. Petz, R. Steadman, M. Streiff, J. McCullough, S. Burks, D. Wages, S. Van Doren, and L. Corash Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease Blood, May 1, 2006; 107(9): 3753 - 3760. [Abstract] [Full Text] [PDF] M. E. Brecher and S. N. Hay Bacterial Contamination of Blood Components Clin. Microbiol. Rev., January 1, 2005; 18(1): 195 - 204. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020